Abstract 2867: Inhibition of BET bromodomain proteins as a therapeutic approach in small cell lung cancer
Anastasia Wyce(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Ramona Plant(Enzo Life Sciences (United States)), Yuchen Bai(The University of Melbourne), Michael Butticello(GlaxoSmithKline (United States)), Jeanne J. Matteo(GlaxoSmithKline (United States)), Yan Degenhardt(Cancer Research Institute), Maureen R. Bleam(GlaxoSmithKline (United States)), David Soong(GlaxoSmithKline (United States)), Christopher Carpenter(Beaumont Hospital, Royal Oak), Peter J. Tummino(Intarcia Therapeutics (United States)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Xiping Zhang(Fudan University), BaoChau Le(GlaxoSmithKline (United States))
Cited by 0
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550